美国斥近20亿美元购买辉瑞及BioNTech新冠疫苗
美国政府斥19.5亿美元购买辉瑞(Pfizer)与德国生物科技公司BioNTech研发的1亿剂新冠病毒疫苗,受消息带动,复星医药(02196.HK)现升5.5%至36.45元,最高见37.3元近两年高。BioNTech是复星医药的战略合作伙伴。
根据美国与辉瑞及BioNTech的协议,美国政府可以有权购买额外5亿剂疫苗,而费用将另外商议。辉瑞发言人称,除非疫苗在大规模临床试验中取得成功并能够顺利生产,否则将不会收取美国政府任何资金。
辉瑞称,希望最快下周就能展开疫苗後期阶段试验,目前有待监管当局批准,集团目标在今年底於全球生产1亿剂疫苗,到明年底产量可能超过13亿剂。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.